Related Experiment Videos
Otilonium bromide: a selective spasmolytic for the gastrointestinal tract
1Preclinical Development Department, Menarini Research SpA, Florence, Italy.
The Journal of International Medical Research
|February 26, 2000
Summary
Otilonium bromide (OB) effectively reduces gastrointestinal spasms and pain in irritable bowel syndrome patients. This spasmolytic drug demonstrates a good safety profile with minimal side effects.
Area of Science:
- Pharmacology
- Gastroenterology
Background:
- Gastrointestinal (GI) motility disorders, such as irritable bowel syndrome (IBS), are common and impact quality of life.
- Otilonium bromide (OB) is a spasmolytic agent used for GI motility disorders.
Purpose of the Study:
- To review the pharmacological properties and clinical efficacy of otilonium bromide (OB).
- To evaluate OB's mechanism of action, pharmacokinetics, and tolerability in managing GI motility disorders.
Main Methods:
- Literature review of experimental, pharmacokinetic, and clinical studies on otilonium bromide.
- Analysis of OB's effects on GI motility, receptor binding, ion channel activity, and clinical outcomes in IBS patients.
Main Results:
- Otilonium bromide inhibits GI motility without affecting gastric secretion or causing atropine-like side effects.
- OB's mechanism involves calcium ion movement interference, calcium channel blockade, and receptor binding (muscarinic, tachykinin NK2).
- Clinical studies show OB superior to placebo and reference drugs in improving IBS symptoms like pain and abdominal distension, with excellent tolerability.
Conclusions:
- Otilonium bromide is a potent spasmolytic agent with a composite, local mechanism of action.
- OB effectively reduces GI hypermotility and modulates visceral sensation, leading to pain relief in IBS.
- The drug exhibits a favorable safety profile, with no serious adverse events reported, confirming its excellent tolerability worldwide.